2‐(3,4‐Dihydroxyphenyl)‐5,7‐dihydroxy‐2,3‐dihydrochromen‐4‐one (eriodictyol), a flavonoid compound, was proved to possess anti‐inflammatory, antioxidative, and antiarthritis activities. However, the effects of eriodictyol on the rheumatoid proliferation, apoptosis, and inflammatory response of arthritis fibroblast‐like synoviocytes (RA‐FLS) remain unclear. Thus, the objective of this study was to examine the effects of eriodictyol on RA‐FLS survival, apoptosis, and inflammatory response, and further explore the potential underlying mechanisms. Our results showed that eriodictyol inhibited the survival of RA‐FLSs and promoted its apoptosis. Eriodictyol significantly reduced RA‐FLS secretion of tumor necrosis factor α, interleukin 6 (IL‐6), IL‐8, and IL‐1β. Furthermore, eriodictyol prevented the activation of the protein kinase B (AKT) pathway and increased the expression of forkhead box O1 (FOXO1) in RA‐FLS. FOXO1 silence reversed the effects of eriodictyol on RA‐FLS survival, apoptosis, and inflammation. In conclusion, these findings indicated that eriodictyol inhibits the cell survival and inflammatory response in RA‐FLS, and the AKT/FOXO1 signaling pathway is involved in the effect of eriodictyol on the RA‐FLS. Thus, eriodictyol might be a potential therapeutic agent for the treatment of rheumatoid arthritis.

No abstract

No abstract

Paired box 3 (PAX3) is a transcription factor and critical regulator of pigment cell development during embryonic development. However, while there have been several studies on PAX3, its expression patterns and precise role remain to be clarified. The present study is an in-depth computational study of tumor-associated gene information, with specific emphasis on the expression of PAX3 in melanoma, using Oncomine along with an investigation of corresponding expression profiles in an array of cancer cell lines through Cancer Cell Line Encyclopedia analysis. Based on Kaplan-Meier analysis, the prognostic value of high PAX3 expression in tissues from patients with melanoma compared with normal tissues was assessed. PAX3 was more highly expressed in male patients with melanoma compared with female patients with melanoma. Using Oncomine and Coexpedia analysis, it was demonstrated that PAX3 expression was clearly associated with SRY-box 10 expression. The survival analysis results revealed that high PAX3 mRNA expression was associated with worse survival rates in patients with melanoma. These results suggested that PAX3 may be a biomarker and essential prognostic factor for melanoma, and provided an important theoretical basis for the development of melanoma treatments.

No abstract